Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:KAYSNASDAQ:PPBTNASDAQ:PRFXNASDAQ:ZVSA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeKAYSKaya$0.04+12.3%$0.04$0.02▼$0.05$760K0.273,327 shs2,031 shsPPBTPurple Biotech$2.32-1.0%$2.47$2.00▼$13.95$3.11M0.5272,419 shs24,193 shsPRFXPainReform$1.45+12.4%$1.97$1.25▼$16.63$2.60M0.631.44 million shs206,977 shsZVSAZyVersa Therapeutics$0.68-4.3%$0.62$0.47▼$6.30$3.39M0.741.56 million shs1.00 million shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceKAYSKaya+12.32%+2.13%-1.79%+9.43%-15.82%PPBTPurple Biotech-1.03%-4.30%-1.45%-16.69%+231,599,900.00%PRFXPainReform+12.40%-14.71%-23.68%-33.18%-23.20%ZVSAZyVersa Therapeutics-4.31%-1.54%+16.86%+11.71%-81.83%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationKAYSKayaN/AN/AN/AN/AN/AN/AN/AN/APPBTPurple Biotech2.51 of 5 stars3.54.00.00.02.20.00.6PRFXPainReform0.7627 of 5 stars0.04.00.00.00.61.70.6ZVSAZyVersa Therapeutics0.3689 of 5 stars0.02.00.00.02.40.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceKAYSKaya 0.00N/AN/AN/APPBTPurple Biotech 3.00Buy$33.001,324.87% UpsidePRFXPainReform 2.00HoldN/AN/AZVSAZyVersa Therapeutics 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookKAYSKaya$10K84.91N/AN/A($0.77) per share-0.05PPBTPurple BiotechN/AN/AN/AN/A$24.74 per shareN/APRFXPainReformN/AN/AN/AN/A$2.08 per shareN/AZVSAZyVersa TherapeuticsN/AN/AN/AN/A$3.40 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateKAYSKaya-$2.08M-$0.08N/A∞N/AN/AN/A-1,044.25%8/13/2025 (Estimated)PPBTPurple Biotech-$7.24M-$2.62N/AN/AN/AN/A-17.84%-15.44%8/15/2025 (Estimated)PRFXPainReform-$14.59M-$147.33N/A∞N/AN/AN/AN/A8/13/2025 (Estimated)ZVSAZyVersa Therapeutics-$9.41MN/A0.00N/AN/AN/A-109.54%-43.95%8/8/2025 (Estimated)Latest KAYS, PPBT, PRFX, and ZVSA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/21/2025Q1 2025KAYSKayaN/A-$0.04N/A-$0.04N/A$0.01 million5/21/2025Q1 2025PPBTPurple BiotechN/A-$0.17N/A-$0.17N/AN/A5/12/2025Q1 2025ZVSAZyVersa Therapeutics-$0.40-$0.73-$0.33-$0.73N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthKAYSKayaN/AN/AN/AN/AN/APPBTPurple BiotechN/AN/AN/AN/AN/APRFXPainReformN/AN/AN/AN/AN/AZVSAZyVersa TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioKAYSKayaN/A0.010.01PPBTPurple BiotechN/A2.722.72PRFXPainReformN/A1.811.81ZVSAZyVersa TherapeuticsN/A0.180.18Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipKAYSKayaN/APPBTPurple Biotech9.64%PRFXPainReform37.28%ZVSAZyVersa Therapeutics3.91%Insider OwnershipCompanyInsider OwnershipKAYSKaya23.52%PPBTPurple Biotech2.98%PRFXPainReform34.40%ZVSAZyVersa Therapeutics0.21%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableKAYSKaya422.17 million16.96 millionNot OptionablePPBTPurple Biotech201.33 million1.29 millionOptionablePRFXPainReform42.01 million1.32 millionNot OptionableZVSAZyVersa Therapeutics24.77 million4.76 millionNot OptionableKAYS, PPBT, PRFX, and ZVSA HeadlinesRecent News About These CompaniesZyVersa Therapeutics Announces Share Purchase Agreement for up to $10 Million in Partnership with Williamsburg Venture Holdings to Fund Clinical Development of Cholesterol ...June 26 at 6:29 PM | morningstar.comMZyVersa Therapeutics Announces First Clinical Site Activation, Initiating Patient Recruitment for Cholesterol Efflux Mediator™ VAR 200’s Phase 2a Clinical Trial in Patients ...June 26 at 6:29 PM | finance.yahoo.comZyVersa Therapeutics Announces First Clinical Site Activation, Initiating Patient Recruitment for Cholesterol Efflux Mediatorâ„¢ VAR 200's Phase 2a Clinical Trial in Patients with Diabetic Kidney Disease (DKD)June 26 at 8:03 AM | globenewswire.comZyVersa Therapeutics Enters Share Purchase Agreement with Williamsburg Venture Holdings to Advance Clinical Development of VAR 200June 25 at 8:38 AM | quiverquant.comQZyVersa Therapeutics Announces Share Purchase Agreement for up to $10 Million in Partnership with Williamsburg Venture Holdings to Fund Clinical Development of Cholesterol Efflux Mediator™ VAR 200June 25 at 7:55 AM | globenewswire.comZyversa Therapeutics Inc News (ZVSA) - Investing.comJune 25 at 7:10 AM | investing.comZVSA - ZyVersa Therapeutics Inc News - MorningstarJune 24 at 4:07 PM | morningstar.comMZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) Sees Large Growth in Short InterestJune 18, 2025 | americanbankingnews.comZyVersa Therapeutics Highlights Published Study Reinforcing That Microglia-driven Inflammation Is Pivotal in Development of Parkinson’s and Alzheimer’s DiseasesMay 22, 2025 | seekingalpha.comZyVersa Therapeutics Highlights New Research Supporting Inflammasome ASC Inhibitor IC 100 as Potential Treatment for Parkinson's DiseaseMay 20, 2025 | quiverquant.comQZyVersa Therapeutics Highlights Published Study Reinforcing That Microglia-driven Inflammation Is Pivotal in Development of Parkinson's and Alzheimer's DiseasesMay 20, 2025 | globenewswire.comZyVersa Therapeutics, Inc. Provides Pipeline and Financial Update: Advances in Clinical Trials for VAR 200 and IC 100May 14, 2025 | nasdaq.comZyVersa Therapeutics Reports First Quarter 2025 Financial Results and Highlights Pipeline ProgressMay 12, 2025 | globenewswire.comZyVersa progresses with obesity inflammation treatmentMay 9, 2025 | uk.investing.comZyVersa Unveils Groundbreaking Potential of Inflammasome Inhibitors in Combination with GLP-1 Agonists to Address Unmet Medical Needs of People Living with Obesity; Provides R&D UpdateMay 7, 2025 | globenewswire.comZyVersa Therapeutics Announces Published Data Showing Inflammasome ASC Inhibitor IC 100 Decreases Microglial Inflammasome Activation and Alpha-Synuclein That Contribute to ...April 29, 2025 | msn.comZyVersa Therapeutics Announces Published Data Showing Inflammasome ASC Inhibitor IC 100 Decreases Microglial Inflammasome Activation and Alpha-Synuclein That Contribute to Neurodegeneration in Parkinson's DiseaseApril 29, 2025 | globenewswire.comZyVersa Therapeutics CEO provides update on inflammasome ASC inhibitor IC 100April 25, 2025 | markets.businessinsider.comZyVersa Therapeutics CEO Issues Shareholder Letter Announcing Transformative R&D Trends for Inflammasome Inhibitors, and Provides Update on Inflammasome ASC Inhibitor IC 100's Development StatusApril 24, 2025 | globenewswire.comZyVersa Therapeutics CEO Issues Shareholder Letter on PARASOL Recommendations Expected to Reduce Drug Development Barrier for Rare Kidney Disease, Focal Segmental ...April 10, 2025 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeKAYS, PPBT, PRFX, and ZVSA Company DescriptionsKaya OTCMKTS:KAYS$0.04 +0.00 (+12.32%) As of 06/26/2025 10:34 AM EasternKaya Holdings, Inc., a vertically integrated legal cannabis enterprise, engages in the operation of psychedelic treatment clinics and medical cannabis dispensaries primarily in the United States. It offers a range of cannabis products, including flower, oils, vape cartridges and cannabis infused confections, baked goods, and beverages. The company also operates retail outlets under the Kaya Shack brand name, as well as offers strain specific cannabis cigarettes under the Kaya Buddies name, and strains of cannabis under the Kaya Farms name. In addition, it is involved in the development of a psychedelic treatment center under The Sacred Mushroom name, that provides its guests access to psilocybin treatments, located in Portland, Oregon. The company was formerly known as Alternative Fuels America, Inc. and changed its name to Kaya Holdings, Inc. in April 2015. Kaya Holdings, Inc. is headquartered in Fort Lauderdale, Florida.Purple Biotech NASDAQ:PPBT$2.32 -0.02 (-1.03%) Closing price 06/26/2025 03:49 PM EasternExtended Trading$2.32 0.00 (-0.04%) As of 06/26/2025 06:25 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its oncology pipeline includes CM24, a humanized monoclonal antibody that blocks the interactions of carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 2 clinical trial for the treatment of pancreatic ductal adenocarcinoma; NT219, a small molecule that targets and inhibits insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 1/2 clinical trials for the treatment recurrent and/or metastatic squamous cell carcinoma of the head and neck cancer or colorectal adenocarcinoma; and IM1240, a multi-valent antibody designed to activate anti-tumoral immune response against 5T4-positive tumors, which is in preclinical stage. The company has collaboration agreement with Bristol Myers Squibb Company to evaluate the combination of CM24 with the PD-1 inhibitor nivolumab in addition to chemotherapy. The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020. The company is headquartered in Rehovot, Israel.PainReform NASDAQ:PRFX$1.45 +0.16 (+12.40%) Closing price 06/26/2025 04:00 PM EasternExtended Trading$1.45 0.00 (0.00%) As of 05:05 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.PainReform Ltd., a clinical stage specialty pharmaceutical company, focuses on the reformulation of established therapeutics and provides an extended period of post-surgical pain relief in Israel. It develops PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia, as well as in Phase 3 clinical trial for pain treatment of patients undergoing bunionectomy and second trial for pain treatment of hernia repair operations. The company was incorporated in 2007 and is based in Tel Aviv, Israel.ZyVersa Therapeutics NASDAQ:ZVSA$0.68 -0.03 (-4.31%) Closing price 06/26/2025 04:00 PM EasternExtended Trading$0.71 +0.03 (+4.50%) As of 05:07 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ZyVersa Therapeutics, Inc., a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. The company develops drug development platforms, including Cholesterol Efflux Mediator VAR 200, an injectable drug, which is in Phase 2a clinical trial to the treatment of renal indications, such as focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney diseases; and Inflammasome ASC Inhibitor IC 100, a humanized monoclonal antibody that is in preclinical stage for treatment of inflammatory diseases comprising acute respiratory syndrome, multiple sclerosis, IgA neuropathy, pancreatic cancer, Parkinson's and Huntington's disease, atherosclerosis, Alzheimer's disease, and obesity. ZyVersa Therapeutics, Inc. was founded in 2014 and is headquartered in Weston, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas NVIDIA’s Stock Price Hits New Highs: This Is What’s Next Micron: A Hot Buy Heats Up, Fresh All-Time Highs Are Coming Super Micro’s Bold $2B Bond Plan Signals 35% Premium Upside Is IBM’s AI Transformation Powering a Sustained Rally? Analysts Supercharge AMD Stock Ahead of Q2 AI Catalyst Amazon: Why Some Are Growing Bearish, and Why They’re Wrong ASML Keeps Buying Back Its Own Stock—Chasing Discount and Upside Astera Labs: AI Infrastructure Play With Significant Growth Ahead Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
